Chronic hepatitis C virus infection: Everyone should be treated

Por Flamm, Steven
Publicado no Clin Liver Dis (Hoboken) (2017)

Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence

Por Flamm, Steven L.
Publicado em 2011

Commentary: Sofosbuvir for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection in Patients Without Treatment Options

Por Flamm, Steven L.
Publicado em 2013

Hepatitis C Virus Infection in Special Populations

Por Flamm, Steven L.
Publicado em 2013

Velpatasvir and sofosbuvir: How will we use a new drug when the old agents work well?

Por Flamm, Steven L.
Publicado no Clin Liver Dis (Hoboken) (2016)

Velpatasvir y sofosbuvir: ¿Por qué utilizar un fármaco nuevo si los antiguos funcionan bien?

Por Flamm, Steven L.
Publicado no Clin Liver Dis (Hoboken) (2016)

Frontiers in the Treatment of Hepatitis C Virus Infection

Por Ahn, Joseph, Flamm, Steven L.
Publicado em 2014

Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy

Por NeSmith, Meghan, Ahn, Joseph, Flamm, Steven L.
Publicado no Gastroenterol Hepatol (N Y) (2016)

Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists

Por Nilles, Kathy M., Caldwell, Stephen H., Flamm, Steven L.
Publicado no Hepatol Commun (2019)

Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study

Por Flamm, Steven L., Pockros, Paul J., Bengtsson, Leif, Friedman, Mark
Publicado no J Clin Transl Hepatol (2014)

Rifaximin has the potential to prevent complications of cirrhosis

Por Flamm, Steven L., Mullen, Kevin D., Heimanson, Zeev, Sanyal, Arun J.
Publicado no Therap Adv Gastroenterol (2018)

Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals

Por Prenner, Stacey B., VanWagner, Lisa B., Flamm, Steven L., Salem, Riad, Lewandowski, Robert J., Kulik, Laura
Publicado no J Hepatol (2017)

Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older

Por Flamm, Steven, Peng, Cheng-Yuan, Shibolet, Oren, Nahass, Ronald, Hwang, Peggy, Barr, Eliav, Robertson, Michael N., Haber, Barbara A.
Publicado no Gerontol Geriatr Med (2019)

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

Por Sherman, Kenneth E., Flamm, Steven L., Afdhal, Nezam H., Nelson, David R., Sulkowski, Mark S., Everson, Gregory T., Fried, Michael W., Adler, Michael, Reesink, Hendrik W., Martin, Marie, Sankoh, Abdul J., Adda, Nathalie, Kauffman, Robert S., George, Shelley, Wright, Christopher I., Poordad, Fred
Publicado em 2011

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

Por Poordad, Fred, Felizarta, Franco, Asatryan, Armen, Sulkowski, Mark S., Reindollar, Robert W., Landis, Charles S., Gordon, Stuart C., Flamm, Steven L., Fried, Michael W., Bernstein, David E., Lin, Chih‐Wei, Liu, Ran, Lovell, Sandra S., Ng, Teresa I., Kort, Jens, Mensa, Federico J.
Publicado no Hepatology (2017)